Back to discover
Drug

Temoporfin

Approved · EMA
Early-to-mid development

Also known as m-THPC, meso-tetrahydroxyphenylchlorin, 2,3-dihydro-5,10,15,20-tetra(m-hydroxyphenyl)porphyrin.

RxNorm115243UNIIFU21S769PF
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Safety and Tumoricidal Effect of Low Dose Temoporfin Photodynamic Therapy in Patients With Inoperable Bile Duct Cancers (Foscan® Study)

Clinical trial2023-08-12Completed · ClinicalTrials.gov

A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) With Temoporfin in Patients With Resectable Primary Non-small Cell Lung Cancer (NSCLC) With Ipsilateral Thoracic Nodal (N1 or N2) or T3/T4 Disease

Clinical trial2018-09-04Completed · ClinicalTrials.gov

A Pilot Study of Interstitial Photodynamic Therapy for Recurrent Squamous Cell Carcinoma of the Oropharynx and Oral Cavity

Clinical trial2014-08-01Withdrawn · ClinicalTrials.gov

Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer

Clinical trial2014-01-01Withdrawn · ClinicalTrials.gov

A Multicenter, Multi-National, Open-Label, Single Group, Single and Multiple Dose Study of Foscan-Mediated Photodynamic Therapy (PDT) for the Palliative Treatment of Recurrent, Refractory or Second Primary Squamous Cell Carcinomas of the Head and Neck in Patients Considered to be Incurable With Surgery or Radiotherapy

Clinical trial2013-12-19Status unknown · ClinicalTrials.gov

Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers - PHASE II PILOT STUDY

Clinical trial2012-03-01Terminated · ClinicalTrials.gov

A Phase II, Open-label, Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma

Clinical trial2011-12-01Primary completion · ClinicalTrials.gov

Approval: Foscan (EMA)

Regulatory2001-10-24EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Temoporfin
Aliases & brands
m-THPCmeso-tetrahydroxyphenylchlorin2,3-dihydro-5,10,15,20-tetra(m-hydroxyphenyl)porphyrin
RxNorm CUI
115243
UNII
FU21S769PF
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2001-10-24
Latest approval
2001-10-24
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2001-10-24Approval
Approval: Foscan (EMA)
Indication: Foscan is indicated for the palliative treatment of patients with advanced head and neck squamous cell carcinoma failing prior therapies and unsuitable for radiotherapy, surgery… Show full indication

Foscan is indicated for the palliative treatment of patients with advanced head and neck squamous cell carcinoma failing prior therapies and unsuitable for radiotherapy, surgery or systemic chemotherapy.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

7 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
7
registered trials across all phases
LATEST COMPLETION 2023
1
Late-stage (III+)
2
Completed
5
Discontinued
PHASE DISTRIBUTIONn = 7
Phase 12Phase 24Phase N / A1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.